Watson Laboratories files raloxifene hydrochloride tablet ANDA
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®.
More... |
All times are GMT -7. The time now is 02:10 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021